NXP-800

N/A

Report date: 2023/08/18 13:47:15
NME

Base Information

Drug NameNXP-800
Drug Alias NameNXP-800CCT361814CCT-361814NXP800
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock factor protein 1 inhibitors
TargetsHeat shock factor protein 1
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsBile Duct Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Institute Of Cancer Research, London
China Registration ClassN/A

Develop Information

Active CompaniesNuvectis Pharma Inc
Inactive CompaniesMayo Clinic
Active IndicationsSolid tumoursOvarian NeoplasmsCarcinoma, Ovarian Epithelial +[4] 
Inactive IndicationsBile Duct NeoplasmsKlatskin TumorCholangiocarcinoma

Other Information

ATC CodeN/A
Related LinksN/A